📊 Consolidated Performance Highlights
Consolidated PAT
₹141.10 Cr ▲ +349%
Consolidated Revenue
₹4,390.50 Cr ▲ +9.17%
Standalone PAT
₹52.20 Cr ▲ Swing to Profit
Standalone Revenue
₹689.30 Cr ▲ +15.19%
Biocon delivered a spectacular turnaround in Q1 FY27, with consolidated net profit surging over 4-fold (349%) to ₹141.10 crore from ₹31.40 crore in the year-ago period. The company swung to a standalone profit of ₹52.20 crore from a loss of ₹8.30 crore in Q1 FY26.
"Biocon's Q1 FY27 results mark a decisive turnaround — the biosimilars business is recovering, and the company is back on a growth trajectory."
— Rupie Times Desk
📌 Point-by-Point Analysis
1️⃣ Consolidated PAT — Spectacular Turnaround
  • Consolidated PAT surged 349% YoY to ₹141.10 crore from ₹31.40 crore 🚀. This is one of the strongest profit growth numbers in the pharma sector. The biosimilars business is clearly recovering and delivering strong earnings.
2️⃣ Standalone PAT — Swing to Profit
  • Standalone PAT swung to a profit of ₹52.20 crore from a loss of ₹8.30 crore in Q1 FY26 ✅. This is a significant improvement, reflecting better operational efficiency and cost management at the parent level.
3️⃣ Revenue Growth — Steady & Consistent
  • Consolidated revenue grew 9.17% YoY to ₹4,390.50 crore 📈. Standalone revenue rose 15.19% to ₹689.30 crore. The revenue growth is steady, but the real story is the explosive profit growth driven by margin expansion.
4️⃣ Stock Performance — Near 52-Week High
  • Stock trading at ₹435.60, up 2.49% on the day, near its 52-week high of ₹447.00 📊. The market has clearly rewarded the strong earnings performance. The stock is up significantly from its 52-week low of ₹331.00.
5️⃣ Biocon's Business — Biosimilars Leader
  • Biocon is a global leader in biosimilars and biologics. The company's portfolio includes biosimilars for cancer, diabetes, and autoimmune diseases. The recent launch of Yesafili (aflibercept biosimilar) in the US is a major growth driver.
📊 Comparison Table
Metric Q1 FY27 Q1 FY26 Growth
Consolidated PAT ₹141.10 Cr ₹31.40 Cr ▲ +349%
Consolidated Revenue ₹4,390.50 Cr ₹4,021.60 Cr ▲ +9.17%
Standalone PAT ₹52.20 Cr ₹-8.30 Cr Swing to Profit
Standalone Revenue ₹689.30 Cr ₹598.40 Cr ▲ +15.19%
Stock Price (CMP) ₹435.60 ~₹350 (Jun 2025) ▲ +24%
🎙️ RUPIE TIMES INSIGHT
🎙️ RUPIE TIMES INSIGHT

"Biocon has delivered one of the most spectacular turnarounds in the pharma sector — consolidated PAT up 349%, standalone swinging from loss to profit."

✅ The Bull Case:

• 349% PAT growth is exceptional — the biosimilars business is firing.

• Standalone swing to profit from loss shows strong parent-level performance.

• Yesafili launch in the US is a significant growth driver for the biosimilars portfolio.

• Near 52-week high — the market is rewarding strong execution.

⚠️ What to Watch:

• Revenue growth is steady but not explosive — 9.17% YoY consolidation.

• Currency fluctuations — the US dollar movement can impact biosimilars revenue.

• Competition — the biosimilars market is becoming increasingly competitive.

📌 Key Takeaway: Biocon is a quality pharma play with a strong biosimilars portfolio. The Q1 FY27 results are a clear confirmation that the company is back on a growth trajectory. For long-term investors, Biocon remains a core holding in the healthcare space. The stock near its 52-week high reflects market confidence in the turnaround story.